EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression

Wiesje Pelkmans iD, Mahnaz Shekari iD, Anna Brugulat-Serrat iD, Gonzalo Sánchez-Benavides iD, Carolina Minguillón iD, Karine Fauria iD, Jose Luis Molinuevo iD, Oriol Grau-Rivera iD, Armand González Escalante, Gwendlyn Kollmorgen, Margherita Carboni iD, Nicholas J Ashton iD und 5 weitere

Alzheimer's & Dementia · 2024-01 · 20 (1) · 483-493

DOI: 10.1002/alz.13450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 10.09.2023. Verfasst von Wiesje Pelkmans und 16 weiteren Autor:innen. Beteiligte Einrichtung: Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 133-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Vetenskapsrådet, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We studied how biomarkers of reactive astrogliosis mediate the pathogenic cascade in the earliest Alzheimer's disease (AD) stages. METHODS We performed path analysis on data from 384 cognitively unimpaired individuals from the ALzheimer and FAmilies (ALFA)+ study using structural equation modeling to quantify the relationships between biomarkers of reactive astrogliosis and the AD pathological cascade. RESULTS Cerebrospinal fluid (CSF) amyloid beta (Aβ) 42/40 was associated with Aβ aggregation on positron emission tomography (PET) and with CSF p‐tau 181 , which was in turn directly associated with CSF neurofilament light (NfL). Plasma glial fibrillary acidic protein (GFAP) mediated the relationship between CSF Aβ 42/40 and Aβ‐PET, and CSF YKL‐40 partly explained the association between Aβ‐PET, p‐tau 181 , and NfL. DISCUSSION Our results suggest that reactive astrogliosis, as indicated by different fluid biomarkers, influences the pathogenic cascade during the preclinical stage of AD. While plasma GFAP mediates the early association between soluble and insoluble Aβ, CSF YKL‐40 mediates the latter association between Aβ and downstream Aβ‐induced tau pathology and tau‐induced neuronal injury. Highlights Lower CSF Aβ 42/40 was directly linked to higher plasma GFAP concentrations. Plasma GFAP partially explained the relationship between soluble Aβ and insoluble Aβ. CSF YKL‐40 mediated Aβ‐induced tau phosphorylation and tau‐induced neuronal injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesAstrocytesBiomarkersChitinase-3-Like Protein 1Glial Fibrillary Acidic ProteinGliosisInflammationIntermediate Filamentstau Proteins

Stichwörter der Autor:innen

AD cascadeastrogliosisbiomarkerschitinase-3-like protein 1 (YKL-40)glial fibrillary acidic protein (GFAP)preclinical Alzheimer's diseasestructural equation modeling

Substanzen

Amyloid beta-PeptidesBiomarkersChitinase-3-Like Protein 1Glial Fibrillary Acidic Proteintau ProteinsCHI3L1 protein, humanGFAP protein, human

Autor:innen und Institutionen

  • Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Universitat Pompeu Fabra, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain.
  • Lundbeck A/S, Copenhagen, Denmark.
  • Roche Diagnostics GmbH, Penzberg, Bavaria, Germany.

ORCID-Profile: Wiesje Pelkmans, Mahnaz Shekari, Anna Brugulat-Serrat, Gonzalo Sánchez-Benavides, Carolina Minguillón, Karine Fauria, Jose Luis Molinuevo, Oriol Grau-Rivera, Margherita Carboni, Nicholas J Ashton, Henrik Zetterberg, Marc Suarez-Calvet, Juan Domingo Gispert

Förderung

  • NIA NIH HHS
  • Vetenskapsrådet
  • Instituto de Salud Carlos III

Zitieren

APA

Pelkmans, W., Shekari, M., Brugulat-Serrat, A., Sánchez-Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau-Rivera, O., González Escalante, A., Kollmorgen, G., Carboni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Suarez-Calvet, M., Gispert, J. D., & ALFA study (2024). Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression. Alzheimer's & Dementia, 20(1), 483-493. https://doi.org/10.1002/alz.13450

Vancouver

Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression. Alzheimer's & Dementia. 2024;20(1):483-493. doi:10.1002/alz.13450

BibTeX
@article{Pelkmans2024,
  author = {Pelkmans, Wiesje and Shekari, Mahnaz and Brugulat-Serrat, Anna and Sánchez-Benavides, Gonzalo and Minguillón, Carolina and Fauria, Karine and Molinuevo, Jose Luis and Grau-Rivera, Oriol and González Escalante, Armand and Kollmorgen, Gwendlyn and Carboni, Margherita and Ashton, Nicholas J and Zetterberg, Henrik and Blennow, Kaj and Suarez-Calvet, Marc and Gispert, Juan Domingo and ALFA study, ALFA study},
  title = {Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {1},
  pages = {483--493},
  doi = {10.1002/alz.13450}
}
Kostenlos starten →